AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36928818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab + nivolumab + chemotherapy (Ipi+Nivo+CT)
Number of subjects: 44
Study 36928818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + chemotherapy (Nivo+CT) in patients without known tumor EGFR/ALK alterations
Number of subjects: 44
Study 36928818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab + nivolumab + chemotherapy (Ipi+Nivo+CT) in patients without known tumor EGFR/ALK alterations
Number of subjects: 44
Study 36928921 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine plus Atezolizumab
Number of subjects: 21
Study 36929131 — intervention group
Group type: EXPERIMENTAL
Intervention: Various clinician rating scales and parent surveys measuring autism-related features and social behaviors
Number of subjects: 399
Study 36929216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-µg BNT162b2 vaccine dose
Number of subjects: 0
Study 36929413 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane eye drops
Number of subjects: 312
Study 36929413 — intervention group
Group type: COMPARATOR
Intervention: 0.6% sodium chloride (NaCl)
Number of subjects: 312
Study 36929533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular JZP458 (recombinant Erwinia chrysanthemi asparaginase)
Number of subjects: 166
Study 36930042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified in the abstract
Number of subjects: 456
Study 36930042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 456
Study 36930105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mini-invasive step-up approach (percutaneous catheter drainage, continuous negative pressure irrigation, percutaneous endoscopic necrosectomy, transgastric necrosectomy)
Number of subjects: 7
Study 36930105 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous negative pressure irrigation (CNPI)
Number of subjects: 7
Study 36930105 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic necrosectomy (PEN)
Number of subjects: 7
Study 36930105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgastric necrosectomy (TN)
Number of subjects: 7
Study 36930148 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Number of subjects: 88
Study 36930148 — intervention group
Group type: COMPARATOR
Intervention: Daily Calorie Restriction (DCR)
Number of subjects: 88
Study 36930148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TRE and DCR)
Number of subjects: 88
Study 36930182 — intervention group
Group type: EXPERIMENTAL
Intervention: Be a Mom intervention
Number of subjects: 1053
Study 36930182 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 1053
Study 36930199 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGMA (single-session intervention of growth mindset on negative emotions)
Number of subjects: 549
Study 36930199 — intervention group
Group type: EXPERIMENTAL
Intervention: SSI-GP (single-session intervention of growth mindset of personality)
Number of subjects: 549
Study 36930199 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 549
Study 36930660 — intervention group
Group type: EXPERIMENTAL
Intervention: Heracure Device
Number of subjects: 10
Study 36930738 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel pulmonary cyst characteristics
Number of subjects: 0
Study 36930781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi practice
Number of subjects: 0
Study 36930781 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36930796 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Diesel Exhaust Exposure
Number of subjects: 0
Study 36930796 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36930857 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular International Prognostic Scoring System (IPSS-M)
Number of subjects: 2876
Study 36930857 — intervention group
Group type: COMPARATOR
Intervention: Revised International Prognostic Scoring System (IPSS-R)
Number of subjects: 2876
Study 36930864 — intervention group
Group type: EXPERIMENTAL
Intervention: Noom Weight (NW)
Number of subjects: 40
Study 36930864 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 40
Study 36931078 — intervention group
Group type: EXPERIMENTAL
Intervention: Q6W dosing of natalizumab (300 mg every 6 weeks)
Number of subjects: 489
Study 36931078 — intervention group
Group type: COMPARATOR
Intervention: Q4W dosing of natalizumab (300 mg every 4 weeks)
Number of subjects: 489
Study 36931078 — intervention group
Group type: EXPERIMENTAL
Intervention: Q6W dosing of natalizumab
Number of subjects: 489
Study 36931110 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural parent training
Number of subjects: 110
Study 36931110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective telephone-assisted self-help parent training
Number of subjects: 110
Study 36931242 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5Δ32/Δ32 haplo-cord transplant
Number of subjects: 1
Study 36931243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CD8
Number of subjects: 0
Study 36931261 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted oocyte activation (AOA) using CaCl2 injection and double ionomycin exposure
Number of subjects: 42
Study 36931261 — intervention group
Group type: COMPARATOR
Intervention: Previous ICSI cycles
Number of subjects: 42
Study 36931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 69
Study 36931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute iron deficiency (S-Ferritin<100 μg/L)
Number of subjects: 69
Study 36931398 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Ferritin levels
Number of subjects: 69
Study 36931398 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP levels
Number of subjects: 69
Study 36931398 — intervention group
Group type: COMPARATOR
Intervention: Different HF phenotypes
Number of subjects: 69
Study 36931426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP) for XR-NTX initiation
Number of subjects: 450
Study 36931426 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (SP) for XR-NTX initiation
Number of subjects: 450
Study 36931453 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 breaths per minute
Number of subjects: 46
Study 36931453 — intervention group
Group type: COMPARATOR
Intervention: 10 breaths per minute
Number of subjects: 46
Study 36931460 — intervention group
Group type: EXPERIMENTAL
Intervention: OaSiS intervention
Number of subjects: 1094
Study 36931460 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1094
Study 36931576 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 186
Study 36931576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 36931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operating Procedures (SOPs) for liquid biopsy management
Number of subjects: 0
Study 36931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical review of existing SOPs
Number of subjects: 0
Study 36931614 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed SOPs in the RENOVATE study
Number of subjects: 0
Study 36931672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 0
Study 36931672 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0
Study 36931680 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (CCS) administration
Number of subjects: 1800
Study 36931682 — intervention group
Group type: EXPERIMENTAL
Intervention: D2B programme 'Kilkari'
Number of subjects: 5095
Study 36931693 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 or 10 mg two times a day
Number of subjects: 0
Study 36931693 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 0
Study 36931746 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-extrusion of ferric pyrophosphate (FePP) with citric acid/trisodium citrate (CA/TSC)
Number of subjects: 0
Study 36931746 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-extrusion of FePP with solubilizers
Number of subjects: 0
Study 36931746 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide (ZnO)
Number of subjects: 0
Study 36931746 — intervention group
Group type: EXPERIMENTAL
Intervention: FePP + CA/TSC
Number of subjects: 0
Study 36931755 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) over 2 months
Number of subjects: 70
Study 36931755 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 36931805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (5 mg to 40 mg daily for 4 weeks)
Number of subjects: 110
Study 36931805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 36931805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 110
Study 36931829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief family-involved treatment (B-FIT)
Number of subjects: 6
Study 36931829 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 6
Study 36931838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognition
Number of subjects: 66
Study 36931838 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Severity
Number of subjects: 66
Study 36931838 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning
Number of subjects: 66
Study 36931838 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition
Number of subjects: 66
Study 36931838 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of Functioning
Number of subjects: 66
Study 36932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived natural killer cell infusion (DNKI)
Number of subjects: 76
Study 36932165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DNKI)
Number of subjects: 76
Study 36932213 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised modality (starting with a knee joint flexion angle of 90°)
Number of subjects: 30
Study 36932213 — intervention group
Group type: COMPARATOR
Intervention: Standardised modality (starting from a conventional chair with 46 cm seat height)
Number of subjects: 30
Study 36932213 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised modality
Number of subjects: 30
Study 36932262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h pre-dose fast followed by a 30-min post-dose fast (2 h-30 min)
Number of subjects: 156
Study 36932262 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h pre-dose fast followed by a 30-min post-dose fast (4 h-30 min)
Number of subjects: 156
Study 36932262 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h pre-dose fast followed by a 30-min post-dose fast (6 h-30 min)
Number of subjects: 156
Study 36932262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h pre-dose fast followed by an overnight post-dose fast (2 h-night)
Number of subjects: 156
Study 36932262 — intervention group
Group type: COMPARATOR
Intervention: Overnight pre-dose fast followed by a 30-min post-dose fast (night-30 min)
Number of subjects: 156
Study 36932321 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and online problem-solving intervention
Number of subjects: 290
Study 36932321 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study 36932346 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of MMR and YF vaccines
Number of subjects: 738
Study 36932356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 47
Study 36932356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 47
Study 36932356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (Aflibercept and Ranibizumab)
Number of subjects: 47
Study 36932361 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0
Study 36932361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36932369 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP for Health intervention (multicomponent behavioral intervention including tailored HIV and PrEP education, motivational interviewing, problem-solving skills, and ongoing navigation support)
Number of subjects: 0
Study 36932369 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (eSOC) control condition (brief educational video on the utility of PrEP for HIV prevention)
Number of subjects: 0
Study 36932416 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 58
Study 36932416 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 58
Study 36932430 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping (BMAC) plus risk assessment and signposting
Number of subjects: 66
Study 36932430 — intervention group
Group type: COMPARATOR
Intervention: Risk assessment and signposting alone
Number of subjects: 66
Study 36932433 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-ILD
Number of subjects: 148
Study 36932645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging (HSI)
Number of subjects: 341
Study 36932645 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 341
Study 36932709 — intervention group
Group type: EXPERIMENTAL
Intervention: UNTOUCHED-like programming of detection cut-offs adopted in 426 (29%) patients immediately after device implantation.
Number of subjects: 1468
Study 36932709 — intervention group
Group type: EXPERIMENTAL
Intervention: UNTOUCHED-like programming of detection cut-offs adopted in 714 (49%) patients at the last follow-up.
Number of subjects: 1468
Study 36932709 — intervention group
Group type: EXPERIMENTAL
Intervention: Median programmed conditional zone cut-off set to 200 bpm (IQR: 200-220) and shock zone cut-off set to 230 bpm (IQR: 210-250) at implantation.
Number of subjects: 1468
Study 36932714 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) management with interruption 52 (IQR 37-62) hours before the procedure and resumption 31 (IQR 21-47) hours later.
Number of subjects: 789
Study 36932714 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) management with interruption and high CHA2DS2-VASc score.
Number of subjects: 789
Study 36932839 — intervention group
Group type: COMPARATOR
Intervention: PCR-confirmed infection with Yersinia spp. (2% in patients without appendicitis)
Number of subjects: 224
Study 36932839 — intervention group
Group type: COMPARATOR
Intervention: Serologic-confirmed infection with Y. enterocolitica
Number of subjects: 224
Study 36932839 — intervention group
Group type: COMPARATOR
Intervention: PCR-confirmed infection with Campylobacter spp.
Number of subjects: 224
Study 36933004 — intervention group
Group type: EXPERIMENTAL
Intervention: Home use of misoprostol (up to 70 days of gestation)
Number of subjects: 273
Study 36933057 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Group Lifestyle Balance intervention (GLB)
Number of subjects: 184
Study 36933057 — intervention group
Group type: COMPARATOR
Intervention: Adaptive GLB Plus intervention (GLB+)
Number of subjects: 184
Study 36933057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GLB and GLB+)
Number of subjects: 184
Study 36933080 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure to anticholinergic and sedative medications (DBI ≥ 1)
Number of subjects: 721
Study 36933080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure to anticholinergic and sedative medications (0 < DBI < 1)
Number of subjects: 721
Study 36933080 — intervention group
Group type: COMPARATOR
Intervention: No exposure to anticholinergic and sedative medications (DBI = 0)
Number of subjects: 721
Study 36933101 — intervention group
Group type: EXPERIMENTAL
Intervention: Handbook intervention for parents; sent in June before students' August matriculation, with motivational interviewing support.
Number of subjects: 919
Study 36933101 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual).
Number of subjects: 919
Study 36933251 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol (head-of-bed elevation within the first 12 hours, followed by sedation, orthostatism, and/or walking as tolerated)
Number of subjects: 208
Study 36933251 — intervention group
Group type: COMPARATOR
Intervention: Bed rest protocol (recumbent with head-of-bed angle inferior to 30° for 48 hours)
Number of subjects: 208
Study 36933251 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol
Number of subjects: 208
Study 36933251 — intervention group
Group type: COMPARATOR
Intervention: Bed rest protocol
Number of subjects: 208
Study 36933290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives with InSHAPE+Weight Watchers program
Number of subjects: 1348
Study 36933290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives with other healthy lifestyle programs (gym membership, Weight Watchers membership, InSHAPE program)
Number of subjects: 1348
Study 36933290 — intervention group
Group type: EXPERIMENTAL
Intervention: InSHAPE+Weight Watchers group receiving additional cash incentives
Number of subjects: 1348
Study 36933351 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous reference ranges for body composition parameters
Number of subjects: 1958
Study 36933552 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM with care coordination
Number of subjects: 834
Study 36933552 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM alone
Number of subjects: 834
Study 36933552 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 834
Study 36933755 — intervention group
Group type: EXPERIMENTAL
Intervention: G1T48 (SERD) combined with N-heterocyclic carbene gold(I) [NHC-Au(I)]
Number of subjects: 1
Study 36933755 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex 23 (G1T48 + NHC-Au(I))
Number of subjects: 1
Study 36933767 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neurodevelopmental impairment (NDI)
Number of subjects: 44
Study 36933767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate neurodevelopmental impairment (NDI)
Number of subjects: 44
Study 36933767 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse outcome (perinatal death or NDI)
Number of subjects: 44
Study 36933767 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral problems
Number of subjects: 44
Study 36933767 — intervention group
Group type: EXPERIMENTAL
Intervention: Special needs education attendance
Number of subjects: 44
Study 36933773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet intervention
Number of subjects: 0
Study 36933773 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual clinical care)
Number of subjects: 0
Study 36933790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Number of subjects: 42
Study 36933790 — intervention group
Group type: COMPARATOR
Intervention: Ad-libitum feeding
Number of subjects: 42
Study 36934142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenously)
Number of subjects: 27
Study 36934142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 27
Study 36934202 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning-based contrast-boosting algorithm on double-low-dose CT (DLD-DL)
Number of subjects: 68
Study 36934202 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (SD)
Number of subjects: 68
Study 36934257 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine in combination with ICBs (anti-CTLA-4 and anti-PD-1)
Number of subjects: 0
Study 36934257 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine with ICBs
Number of subjects: 0
Study 36934257 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 0
Study 36934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chole-risk score
Number of subjects: 1253
Study 36934276 — intervention group
Group type: EXPERIMENTAL
Intervention: POSSUM Physiological Score (PS)
Number of subjects: 1253
Study 36934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chole-POSSUM score (cutoff of 25)
Number of subjects: 1253
Study 36934276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity and mortality
Number of subjects: 1253
Study 36934286 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained liner (CL)
Number of subjects: 146
Study 36934286 — intervention group
Group type: COMPARATOR
Intervention: Dual mobility cup (DM)
Number of subjects: 146
Study 36934327 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line Infliximab (FL-IFX), five 5-mg/kg infusions over 22 weeks
Number of subjects: 86
Study 36934327 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CONV), exclusive enteral nutrition or oral prednisolone
Number of subjects: 86
Study 36934327 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line Infliximab (FL-IFX)
Number of subjects: 86
Study 36934327 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 86
Study 36934341 — intervention group
Group type: EXPERIMENTAL
Intervention: interprof ACT
Number of subjects: 643
Study 36934341 — intervention group
Group type: COMPARATOR
Intervention: usual care (control)
Number of subjects: 643
Study 36934366 — intervention group
Group type: EXPERIMENTAL
Intervention: Danavorexton (TAK-925) 0.1 mg/kg
Number of subjects: 2
Study 36934371 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36934668 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (400 mg/day) for two months
Number of subjects: 19
Study 36934668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg/day) for two months
Number of subjects: 19
Study 36934731 — intervention group
Group type: COMPARATOR
Intervention: PCV13 14-week 1+1 group
Number of subjects: 600
Study 36934731 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 2+1 group
Number of subjects: 600
Study 36934731 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 14-week 1+1 group
Number of subjects: 600
Study 36934731 — intervention group
Group type: COMPARATOR
Intervention: PCV10 2+1 group
Number of subjects: 600
Study 36934731 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 1+1 groups
Number of subjects: 600